BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

385 related articles for article (PubMed ID: 30259750)

  • 41. A tumor microenvironment responsive biodegradable CaCO
    Liu Y; Pan Y; Cao W; Xia F; Liu B; Niu J; Alfranca G; Sun X; Ma L; de la Fuente JM; Song J; Ni J; Cui D
    Theranostics; 2019; 9(23):6867-6884. PubMed ID: 31660074
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Immune reprogramming via PD-1 inhibition enhances early-stage lung cancer survival.
    Markowitz GJ; Havel LS; Crowley MJ; Ban Y; Lee SB; Thalappillil JS; Narula N; Bhinder B; Elemento O; Wong ST; Gao D; Altorki NK; Mittal V
    JCI Insight; 2018 Jul; 3(13):. PubMed ID: 29997286
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Poly Lactic-co-Glycolic Acid Nanoparticles Containing Human Gastric Tumor Lysates as Antigen Delivery Vehicles for Dendritic Cell-Based Antitumor Immunotherapy.
    Kohnepoushi C; Nejati V; Delirezh N; Biparva P
    Immunol Invest; 2019 Nov; 48(8):794-808. PubMed ID: 31094258
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Plant Viral Nanoparticle Conjugated with Anti-PD-1 Peptide for Ovarian Cancer Immunotherapy.
    Gautam A; Beiss V; Wang C; Wang L; Steinmetz NF
    Int J Mol Sci; 2021 Sep; 22(18):. PubMed ID: 34575893
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Clinical and Translational Advances in Glioma Immunotherapy.
    Bunse L; Bunse T; Krämer C; Chih YC; Platten M
    Neurotherapeutics; 2022 Oct; 19(6):1799-1817. PubMed ID: 36303101
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Dynamic Changes in PD-L1 Expression and Immune Infiltrates Early During Treatment Predict Response to PD-1 Blockade in Melanoma.
    Vilain RE; Menzies AM; Wilmott JS; Kakavand H; Madore J; Guminski A; Liniker E; Kong BY; Cooper AJ; Howle JR; Saw RPM; Jakrot V; Lo S; Thompson JF; Carlino MS; Kefford RF; Long GV; Scolyer RA
    Clin Cancer Res; 2017 Sep; 23(17):5024-5033. PubMed ID: 28512174
    [No Abstract]   [Full Text] [Related]  

  • 47. Immune Checkpoint Blockade Mediated by a Small-Molecule Nanoinhibitor Targeting the PD-1/PD-L1 Pathway Synergizes with Photodynamic Therapy to Elicit Antitumor Immunity and Antimetastatic Effects on Breast Cancer.
    Zhang R; Zhu Z; Lv H; Li F; Sun S; Li J; Lee CS
    Small; 2019 Dec; 15(49):e1903881. PubMed ID: 31702880
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Lipid Nanoparticle Assisted mRNA Delivery for Potent Cancer Immunotherapy.
    Oberli MA; Reichmuth AM; Dorkin JR; Mitchell MJ; Fenton OS; Jaklenec A; Anderson DG; Langer R; Blankschtein D
    Nano Lett; 2017 Mar; 17(3):1326-1335. PubMed ID: 28273716
    [TBL] [Abstract][Full Text] [Related]  

  • 49. RIG-I-based immunotherapy enhances survival in preclinical AML models and sensitizes AML cells to checkpoint blockade.
    Ruzicka M; Koenig LM; Formisano S; Boehmer DFR; Vick B; Heuer EM; Meinl H; Kocheise L; Zeitlhöfler M; Ahlfeld J; Kobold S; Endres S; Subklewe M; Duewell P; Schnurr M; Jeremias I; Lichtenegger FS; Rothenfusser S
    Leukemia; 2020 Apr; 34(4):1017-1026. PubMed ID: 31740809
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Intratumoral STING Activation with T-cell Checkpoint Modulation Generates Systemic Antitumor Immunity.
    Ager CR; Reilley MJ; Nicholas C; Bartkowiak T; Jaiswal AR; Curran MA
    Cancer Immunol Res; 2017 Aug; 5(8):676-684. PubMed ID: 28674082
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Glycocalyx-Mimicking Nanoparticles Improve Anti-PD-L1 Cancer Immunotherapy through Reversion of Tumor-Associated Macrophages.
    Zhang Y; Wu L; Li Z; Zhang W; Luo F; Chu Y; Chen G
    Biomacromolecules; 2018 Jun; 19(6):2098-2108. PubMed ID: 29634251
    [TBL] [Abstract][Full Text] [Related]  

  • 52. MnO
    Tang S; Zhou L; He H; Cui L; Ren Z; Tai Y; Xie Z; Cao Y; Meng D; Liu Q; Wu Y; Jiang J; Zhou X
    Biomaterials; 2022 Sep; 288():121706. PubMed ID: 35953328
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Concurrent PD-1 Blockade Negates the Effects of OX40 Agonist Antibody in Combination Immunotherapy through Inducing T-cell Apoptosis.
    Shrimali RK; Ahmad S; Verma V; Zeng P; Ananth S; Gaur P; Gittelman RM; Yusko E; Sanders C; Robins H; Hammond SA; Janik JE; Mkrtichyan M; Gupta S; Khleif SN
    Cancer Immunol Res; 2017 Sep; 5(9):755-766. PubMed ID: 28848055
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Photothermally activatable PDA immune nanomedicine combined with PD-L1 checkpoint blockade for antimetastatic cancer photoimmunotherapy.
    Lu Q; Qi S; Li P; Yang L; Yang S; Wang Y; Cheng Y; Song Y; Wang S; Tan F; Li N
    J Mater Chem B; 2019 Apr; 7(15):2499-2511. PubMed ID: 32255127
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Supramolecular Lipid Nanoparticles Based on Host-Guest Recognition: A New Generation Delivery System of mRNA Vaccines For Cancer Immunotherapy.
    Qi S; Zhang X; Yu X; Jin L; Yang K; Wang Y; Feng Y; Lei J; Mao Z; Yu G
    Adv Mater; 2024 Jun; 36(23):e2311574. PubMed ID: 38433564
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Nanotechnology-Based Cancer Vaccine.
    Alshamsan A
    Methods Mol Biol; 2017; 1530():257-270. PubMed ID: 28150207
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Polymer nanoparticles for enhanced immune response: combined delivery of tumor antigen and small interference RNA for immunosuppressive gene to dendritic cells.
    Heo MB; Cho MY; Lim YT
    Acta Biomater; 2014 May; 10(5):2169-76. PubMed ID: 24394635
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Personalized approaches to active immunotherapy in cancer.
    Ophir E; Bobisse S; Coukos G; Harari A; Kandalaft LE
    Biochim Biophys Acta; 2016 Jan; 1865(1):72-82. PubMed ID: 26241169
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Core-shell nanoscale coordination polymers combine chemotherapy and photodynamic therapy to potentiate checkpoint blockade cancer immunotherapy.
    He C; Duan X; Guo N; Chan C; Poon C; Weichselbaum RR; Lin W
    Nat Commun; 2016 Aug; 7():12499. PubMed ID: 27530650
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Contribution of systemic and somatic factors to clinical response and resistance to PD-L1 blockade in urothelial cancer: An exploratory multi-omic analysis.
    Snyder A; Nathanson T; Funt SA; Ahuja A; Buros Novik J; Hellmann MD; Chang E; Aksoy BA; Al-Ahmadie H; Yusko E; Vignali M; Benzeno S; Boyd M; Moran M; Iyer G; Robins HS; Mardis ER; Merghoub T; Hammerbacher J; Rosenberg JE; Bajorin DF
    PLoS Med; 2017 May; 14(5):e1002309. PubMed ID: 28552987
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 20.